EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access

Effect of a Novel GLP ‐1 Analogue Ecnoglutide on the Pharmacokinetics of Rosuvastatin and Digoxin in Healthy Participants

Fengshan Li iD, Chunfeng Du, Qin Yu, Shiyin Feng, Linrui Cai, Zhuo Chen, Qin Zou, Weiyi Guo, Dan Du, Feng Hu, Xiaohong Liu, Yalin Huang und 8 weitere

Diabetes, Obesity and Metabolism · 2026-09 · 28 (9) · 8128-8135

DOI: 10.1111/dom.70880 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 17.06.2026. Verfasst von Fengshan Li und 19 weiteren Autor:innen. Beteiligte Einrichtung: National Drug Clinical Trial Institution of West China Second University Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Rosuvastatin Calcium, Digoxin, Glucagon-Like Peptide 1, Hydroxymethylglutaryl-CoA Reductase Inhibitors. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Evaluate ecnoglutide (XW003) effects on rosuvastatin and digoxin pharmacokinetics (PKs) in healthy adults.

Methods

This was an open‐label, single‐sequence crossover Phase 1 study. Eligible participants received rosuvastatin (10 mg, single dose) and digoxin (0.25 mg, single dose) in two periods: Once before subcutaneous treatment with ecnoglutide and once during steady‐state subcutaneous ecnoglutide (1.2 mg). Coadministration effect was assessed via PK parameters of both drugs.

Results

A total of 28 volunteers received at least one dose of study drug. Co‐administration of ecnoglutide did not affect rosuvastatin and digoxin to a clinically relevant degree. For the area under the concentration‐time curve from time zero to infinity, the geometric mean (GM) ratio (with ecnoglutide vs. alone) [90% confidence interval (CI)] was 106% (94%, 120%) for rosuvastatin and 84% (76%, 94%) for digoxin. Additionally, the maximum plasma concentration ( C max ) of digoxin decreased from 1.39 to 1.31 ng/mL but remained within the therapeutic window. The most common adverse events (AEs) were weight loss and gastrointestinal AEs, which are pharmacologically associated with glucagon‐like peptide‐1 (GLP‐1). No serious AEs were reported. Notably, ecnoglutide treatment led to substantial body weight reduction, with a mean decrease of 11.2% across the 14‐week intervention.

Conclusion

Based on the PK and safety evaluations, ecnoglutide does not cause clinically significant PK interactions with rosuvastatin or digoxin. Consequently, no dose adjustments for rosuvastatin or digoxin are required when ecnoglutide is co‐administered. However, close clinical and plasma monitoring is advised during the coadministration of digoxin, especially in patients with renal impairment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rosuvastatin CalciumDigoxinGlucagon-Like Peptide 1Hydroxymethylglutaryl-CoA Reductase InhibitorsHumansFemaleAdultMaleDrug InteractionsCross-Over StudiesMiddle AgedYoung AdultHealthy Volunteers

Stichwörter der Autor:innen

drug–drug interactionecnoglutide (XW003)glucagon‐like peptide‐1 analogueobesity

Substanzen

Rosuvastatin CalciumDigoxinGlucagon-Like Peptide 1Hydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • National Drug Clinical Trial Institution of West China Second University Hospital, Sichuan University, Chengdu, China.
  • Children's Medicine Key Laboratory of Sichuan Province, West China Second University Hospital, Sichuan University, Chengdu, China.
  • Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu, China.
  • Hangzhou Sciwind Biosciences Co., Ltd., Hangzhou, China.

ORCID-Profile: Fengshan Li

Zitieren

APA

Li, F., Du, C., Yu, Q., Feng, S., Cai, L., Chen, Z., Zou, Q., Guo, W., Du, D., Hu, F., Liu, X., Huang, Y., Shi, S., Shi, W., Guan, L., Yang, L., Zheng, Q., Li, Y., Liu, R., & Yang, M. (2026). Effect of a Novel GLP ‐1 Analogue Ecnoglutide on the Pharmacokinetics of Rosuvastatin and Digoxin in Healthy Participants. Diabetes, Obesity and Metabolism, 28(9), 8128-8135. https://doi.org/10.1111/dom.70880

Vancouver

Li F, Du C, Yu Q, Feng S, Cai L, Chen Z, et al. Effect of a Novel GLP ‐1 Analogue Ecnoglutide on the Pharmacokinetics of Rosuvastatin and Digoxin in Healthy Participants. Diabetes, Obesity and Metabolism. 2026;28(9):8128-8135. doi:10.1111/dom.70880

BibTeX
@article{Li2026,
  author = {Li, Fengshan and Du, Chunfeng and Yu, Qin and Feng, Shiyin and Cai, Linrui and Chen, Zhuo and Zou, Qin and Guo, Weiyi and Du, Dan and Hu, Feng and Liu, Xiaohong and Huang, Yalin and Shi, Shuxia and Shi, Wei and Guan, Lei and Yang, Liu and Zheng, Qing and Li, Yao and Liu, Rui and Yang, Ming},
  title = {Effect of a Novel GLP ‐1 Analogue Ecnoglutide on the Pharmacokinetics of Rosuvastatin and Digoxin in Healthy Participants},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {9},
  pages = {8128--8135},
  doi = {10.1111/dom.70880}
}
Kostenlos starten →